[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100637118":3},{"organization":4,"outcomesModule":7,"designInfo":21,"detailedDescription":20,"studyPopulation":20,"armGroups":27,"interventions":35,"overallOfficials":45,"centralContacts":49,"locations":54,"responsibleParty":71,"collaborators":20,"id":73,"slug":20,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":20,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":20,"studyType":85,"phases":86,"briefSummary":87,"conditions":88,"keywords":20,"overallStatus":91,"whyStopped":20,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Peking University Cancer Hospital & Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":20},[9,13,16],{"measure":10,"description":11,"timeFrame":12},"Radiation Dosimetry of 68Ga-MY","Radiation Dosimetry Organ-absorbed doses (mGy\u002FMBq) and effective dose (mSv\u002FMBq) calculated from PET\u002FCT data using OLINDA\u002FEXM software based on the MIRD schema. Organs assessed include, but are not limited to, the liver, spleen, kidneys, lungs, heart, bone marrow, and urinary bladder.","1. From the start of drug administration to 14 days after injection 2.Dynamic PET\u002FCT scanning from 0 to 40 minutes post-injection, followed by static scans at 1 hour, 2 hours, and 3 hours post-injection. 3.Prior to each patient injection.",{"measure":14,"description":15,"timeFrame":12},"Standardized Uptake Value (SUV)","Parameters of SUV The maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean) and tumor\u002Fbackground ratio (SUVR) of 68Ga-MY in target lesions were observed. SUVR was calculated as the SUVmax of the target lesion divided by the SUVmean of the reference normal tissue.",{"measure":17,"description":18,"timeFrame":19},"The ratio of Tumor SUV to background SUV (SUVR)","SUVR was calculated as the SUVmax of the target lesion divided by the SUVmean of the reference normal tissue.","1. From the start of drug administration to 14 days after injection 2.Dynamic PET\u002FCT scanning from 0 to 40 minutes post-injection, followed by static scans at 1 hour, 2 hours, and 3 hours post-injection. 3.Prior to each patient injection",null,{"allocation":22,"interventionModel":23,"interventionModelDescription":20,"primaryPurpose":24,"observationalModel":20,"timePerspective":20,"maskingInfo":25},"NA","SINGLE_GROUP","DIAGNOSTIC",{"masking":26,"maskingDescription":20,"whoMasked":20},"NONE",[28],{"label":29,"type":30,"description":31,"interventionNames":32},"68Ga-MY PET Imaging","EXPERIMENTAL","All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-MY PET\u002FCT scans.After the participant rests quietly for 40 minutes or 1 hour, whole-body imaging of the head and torso will be performed using a United Imaging uEXPLORER Whole-Body PET\u002FCT scanner at 1 h, 2 h, and 3 h post-injection. The scan range will cover from the vertex to the upper third of the thighs. Participants who required a dynamic scan underwent a 40-min serial scan after injection of 68Ga-MY. PET\u002FCT static imaging was performed at 2 h and 3 h after injection.",[33,34],"Drug: 18F-FDG","Drug: 68Ga-MY",[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":20},"DRUG","18F-FDG","All study participants will undergo one 18F-FDG PET\u002FCT scan.",[29],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":20},"68Ga-MY","68Ga-MY is an investigational tracer, and all participants will undergo 68Ga-MY scanning.",[29],[46],{"name":47,"affiliation":5,"role":48},"Hua Zhu","PRINCIPAL_INVESTIGATOR",[50],{"name":47,"role":51,"phone":52,"phoneExt":20,"email":53},"CONTACT","010-88196495","zhuhuaBCH@pku.edu.cn",[55],{"facility":56,"status":20,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Beijing Cancer Hospital","Beijing","Beijing Municipality","100142","China","CN",{"type":63,"coordinates":64},"Point",[65,66],116.39723,39.9075,{"lat":66,"lon":65},[69],{"name":47,"role":51,"phone":70,"phoneExt":20,"email":53},"+86 010-88196495",{"type":72,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100637118",false,"NCT07589101","5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors","Preparation of 5T4 Tumor Novel Target Nanobody PET Probe and Clinical Translation in Lung Cancer","Inclusion Criteria:\n\n1. Patients with solid tumors;\n2. Presence of measurable lesions on imaging examinations;\n3. Expected survival ≥12 weeks.\n\nExclusion Criteria:\n\n1. Severe hepatic or renal dysfunction;\n2. Women who are planning pregnancy, pregnant, or breastfeeding;\n3. Unable to remain in supine position for 30 minutes;\n4. Refusal to participate in this clinical study;\n5. Diagnosis of claustrophobia or other psychiatric disorders;\n6. Other conditions deemed by the investigator as inappropriate for participation in the trial.","ALL","18 Years","70 Years",{"count":83,"type":84},20,"ESTIMATED","INTERVENTIONAL",[22],"This study aims to evaluate a novel 5T4 targeted nanobody PET imaging tracer, 68Ga-MY, for the detection and evaluation of solid tumors.\n\nThe 5T4 oncofoetal antigen is considered a valuable tumor-associated antigen, which is expressed in many different cancers, but is rarely expressed in normal adult tissues. And cell surface expression of 5T4 is an important property for antibody-targeted therapies. It has been shown that 5T4 is expressed on tumour-initiating cells (TICs) and associated with worse clinical outcome. Moreover, decreased adherence due to 5T4 expression may be associated with cancer spread.\n\nIn this single-center, open-label, self-controlled study, approximately 20 patients with suspected or confirmed solid tumors will undergo PET\u002FCT imaging using 68Ga-MY. The imaging results will be compared with 18F-FDG. The study will assess tracer uptake in tumor lesions and compare diagnostic performance between imaging methods. The results may help determine whether 68Ga-MY PET\u002FCT can improve tumor detection, staging, and clinical evaluation in patients with solid tumors.",[89,90],"Lung Cancer","Breast Cancer","NOT_YET_RECRUITING","2026-05-08",{"date":94,"type":95},"2026-05-15","ACTUAL",{"date":97,"type":84},"2026-06-01",{"date":99,"type":84},"2027-12-30",{"name":5,"class":6},1]